Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
Open Access
- 9 October 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10), e75361
- https://doi.org/10.1371/journal.pone.0075361
Abstract
Galectin-3 protein is critical to the development of liver fibrosis because galectin-3 null mice have attenuated fibrosis after liver injury. Therefore, we examined the ability of novel complex carbohydrate galectin inhibitors to treat toxin-induced fibrosis and cirrhosis. Fibrosis was induced in rats by intraperitoneal injections with thioacetamide (TAA) and groups were treated with vehicle, GR-MD-02 (galactoarabino-rhamnogalaturonan) or GM-CT-01 (galactomannan). In initial experiments, 4 weeks of treatment with GR-MD-02 following completion of 8 weeks of TAA significantly reduced collagen content by almost 50% based on Sirius red staining. Rats were then exposed to more intense and longer TAA treatment, which included either GR-MD-02 or GM-CT-01 during weeks 8 through 11. TAA rats treated with vehicle developed extensive fibrosis and pathological stage 6 Ishak fibrosis, or cirrhosis. Treatment with either GR-MD-02 (90 mg/kg ip) or GM-CT-01 (180 mg/kg ip) given once weekly during weeks 8–11 led to marked reduction in fibrosis with reduction in portal and septal galectin-3 positive macrophages and reduction in portal pressure. Vehicle-treated animals had cirrhosis whereas in the treated animals the fibrosis stage was significantly reduced, with evidence of resolved or resolving cirrhosis and reduced portal inflammation and ballooning. In this model of toxin-induced liver fibrosis, treatment with two galectin protein inhibitors with different chemical compositions significantly reduced fibrosis, reversed cirrhosis, reduced galectin-3 expressing portal and septal macrophages, and reduced portal pressure. These findings suggest a potential role of these drugs in human liver fibrosis and cirrhosis.Keywords
This publication has 44 references indexed in Scilit:
- Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosisProceedings of the National Academy of Sciences of the United States of America, 2012
- Metchnikoff's policemen: macrophages in development, homeostasis and regenerationTrends in Molecular Medicine, 2011
- Structural features for α-galactomannan binding to galectin-1Glycobiology, 2011
- When Galectins Recognize Glycans: From Biochemistry to Physiology and Back AgainBiochemistry, 2011
- Structural aspects of binding of α-linked digalactosides to human galectin-1Glycobiology, 2011
- Mutational Tuning of Galectin-3 Specificity and Biological FunctionOnline Journal of Public Health Informatics, 2010
- Dynamics of galectin-3 in the nucleus and cytoplasmBiochimica et Biophysica Acta (BBA) - General Subjects, 2010
- The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin–glycan interactions at the cell surfaceBiochemical Journal, 2009
- The -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domainGlycobiology, 2009
- Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammationClinical and Experimental Immunology, 2008